{"symbol": "LLY", "publishedDate": "2023-10-26 09:05:00", "publisher": "The Motley Fool", "title": "Will Eli Lilly Stock Be Worth More Than Tesla Stock by 2030?", "image": "https://images.financialmodelingprep.com/news/will-eli-lilly-stock-be-worth-more-than-tesla-20231026.jpg", "site": "fool.com", "text": "Eli Lilly has the potential to be a huge name in weight loss by the end of the decade. Tesla has significant potential in the electric vehicle market, but it could face a lot of competition.", "url": "https://www.fool.com/investing/2023/10/26/will-eli-lilly-stock-be-worth-more-than-tesla-stoc/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-26T09:05:00-04:00", "date_et": "2023-10-26"}
{"symbol": "LLY", "publishedDate": "2023-10-26 10:00:00", "publisher": "PRNewsWire", "title": "Lilly to Participate in UBS Biopharma Conference 2023", "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-ubs-biopharma-conference-2023-20231026.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m.", "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-ubs-biopharma-conference-2023-301967876.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-26T10:00:00-04:00", "date_et": "2023-10-26"}
{"symbol": "LLY", "publishedDate": "2023-10-26 11:19:18", "publisher": "Zacks Investment Research", "title": "Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline", "image": "https://images.financialmodelingprep.com/news/earnings-preview-eli-lilly-lly-q3-earnings-expected-to-20231026.jpg", "site": "zacks.com", "text": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://www.zacks.com/stock/news/2172796/earnings-preview-eli-lilly-lly-q3-earnings-expected-to-decline", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-26T11:19:18-04:00", "date_et": "2023-10-26"}
{"symbol": "LLY", "publishedDate": "2023-10-26 18:24:00", "publisher": "PRNewsWire", "title": "FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis", "image": "https://images.financialmodelingprep.com/news/fda-approves-lillys-omvoh-mirikizumabmrkz-a-firstinclass-treatment-for-20231026.jpg", "site": "prnewswire.com", "text": "Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Marking a significant milestone, Omvoh is the only UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to UC.", "url": "https://www.prnewswire.com/news-releases/fda-approves-lillys-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301969505.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-26T18:24:00-04:00", "date_et": "2023-10-26"}
{"symbol": "LLY", "publishedDate": "2023-10-26 18:47:01", "publisher": "Reuters", "title": "Eli Lilly's bowel disease drug gets US FDA's approval in adults", "image": "https://images.financialmodelingprep.com/news/eli-lillys-bowel-disease-drug-gets-us-fdas-approval-20231026.jpg", "site": "reuters.com", "text": "Eli Lilly and Company said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderately to severely active ulcerative colitis, a type of chronic inflammatory bowel disease.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-bowel-disease-drug-gets-us-fdas-approval-adults-2023-10-26/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-26T18:47:01-04:00", "date_et": "2023-10-26"}
{"symbol": "LLY", "publishedDate": "2023-10-27 03:52:53", "publisher": "Proactive Investors", "title": "Eli Lilly bowel disease drug approved in US", "image": "https://images.financialmodelingprep.com/news/eli-lilly-bowel-disease-drug-approved-in-us-20231027.jpg", "site": "proactiveinvestors.com", "text": "Eli Lilly and Co (NYSE:LLY) has announced that its Omvoh drug has been approved by the US Food and Drug Administration to treat types of inflammatory bowel disease. Following a third-phase 12-week clinical trial, in which Omvoh prompted responses in 65% of patients and remission in 24%, Eli Lilly announced the approval on Thursday.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1031188?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-27T03:52:53-04:00", "date_et": "2023-10-27"}
{"symbol": "LLY", "publishedDate": "2023-10-27 14:58:52", "publisher": "Proactive Investors", "title": "Eli Lilly diabetes drug Mounjaro will be in focus when the drugmaker reports earnings next week", "image": "https://images.financialmodelingprep.com/news/eli-lilly-diabetes-drug-mounjaro-will-be-in-focus-20231027.jpg", "site": "proactiveinvestors.com", "text": "Eli Lilly and Co (NYSE:LLY) is scheduled to report earnings before the market opens on Thursday, with analysts expecting revenue growth but an earnings decline.  The drugmaker is expected to post a third-quarter adjusted loss of $0.15 per share on revenue of $8.95 billion, compared to earnings of $1.61 per share on revenue of $6.94 billion a year earlier.", "url": "https://www.proactiveinvestors.com/companies/news/1031280?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-27T14:58:52-04:00", "date_et": "2023-10-27"}
{"symbol": "LLY", "publishedDate": "2023-10-28 08:45:00", "publisher": "The Motley Fool", "title": "Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?", "image": "https://images.financialmodelingprep.com/news/roche-lilly-or-pfizer-whos-the-winner-in-ibd-20231028.jpg", "site": "fool.com", "text": "Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.", "url": "https://www.fool.com/investing/2023/10/28/roche-lilly-or-pfizer-whos-the-winner-in-ibd-wars/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-28T08:45:00-04:00", "date_et": "2023-10-28"}
{"symbol": "LLY", "publishedDate": "2023-10-30 07:05:00", "publisher": "Seeking Alpha", "title": "Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore", "image": "https://images.financialmodelingprep.com/news/albemarle-vs-eli-lilly-1-potentially-set-to-soar-and-20231030.jpg", "site": "seekingalpha.com", "text": "Valuation and fundamentals always matter, driving 97% of long-term stock returns. The market is capable of incredible \"fat pitch\" discounts and also creates insane bubbles. Albemarle Corporation is the world's leading lithium miner and is 65% undervalued, trading at less than 6X earnings, the lowest P/E in over 20 years.", "url": "https://seekingalpha.com/article/4644385-albemarle-vs-eli-lilly-1-potentially-set-to-soar-and-1-bubble-stock-to-ignore", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-30T07:05:00-04:00", "date_et": "2023-10-30"}
{"symbol": "LLY", "publishedDate": "2023-10-30 12:03:02", "publisher": "Zacks Investment Research", "title": "Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3", "image": "https://images.financialmodelingprep.com/news/busy-week-for-earnings-fed-reports-mcd-on-beat-20231030.jpg", "site": "zacks.com", "text": "Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.", "url": "https://www.zacks.com/stock/news/2174606/busy-week-for-earnings-fed-reports-mcd-on-beat-in-q3", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-30T12:03:02-04:00", "date_et": "2023-10-30"}
{"symbol": "LLY", "publishedDate": "2023-10-31 08:37:02", "publisher": "Proactive Investors", "title": "Beam Therapeutics up 10% on $600m Lilly deal", "image": "https://images.financialmodelingprep.com/news/beam-therapeutics-up-10-on-600m-lilly-deal-20231031.jpg", "site": "proactiveinvestors.com", "text": "Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and Co (NYSE:LLY). An upfront $250 million cash and paper payment could balloon to $600 million based on milestones.", "url": "https://www.proactiveinvestors.com/companies/news/1031525?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-31T08:37:02-04:00", "date_et": "2023-10-31"}
{"symbol": "LLY", "publishedDate": "2023-10-31 10:12:33", "publisher": "The Motley Fool", "title": "Eli Lilly Stock Has Quadrupled in 3 Years. Could a Weight-Loss Drug Approval Make It Happen Again?", "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-has-quadrupled-in-3-years-could-20231031.jpg", "site": "fool.com", "text": "Speculation and hype created the bulk of Eli Lilly's bullishness of late rather than plausible fundamentals. The rampant speculation around Mounjaro leaves Lilly stock highly vulnerable to bearish volatility.", "url": "https://www.fool.com/investing/2023/10/31/eli-lilly-stock-quadrupled-weight-loss-drug/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-31T10:12:33-04:00", "date_et": "2023-10-31"}
{"symbol": "LLY", "publishedDate": "2023-10-31 13:54:52", "publisher": "Investors Business Daily", "title": "Verve Stock Soars On $250 Million Eli Lilly Deal", "image": "https://images.financialmodelingprep.com/news/verve-stock-soars-on-250-million-eli-lilly-deal-20231031.jpg", "site": "investors.com", "text": "Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.", "url": "https://www.investors.com/news/technology/verv-stock-skyrockets-after-lilly-inks-deal-for-its-gene-editing-drugs/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-31T13:54:52-04:00", "date_et": "2023-10-31"}
{"symbol": "LLY", "publishedDate": "2023-10-31 16:48:26", "publisher": "InvestorPlace", "title": "AI-Powered Investing: 3 Promising Stocks for 2024", "image": "https://images.financialmodelingprep.com/news/aipowered-investing-3-promising-stocks-for-2024-20231031.jpg", "site": "investorplace.com", "text": "Stock predictions by AI (artificial intelligence) are becoming more popular with investors.  More actively managed ETFs are launching driven by AI.", "url": "https://investorplace.com/2023/10/ai-powered-investing-3-promising-stocks-for-2024/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-31T16:48:26-04:00", "date_et": "2023-10-31"}
{"symbol": "LLY", "publishedDate": "2023-10-31 19:09:02", "publisher": "The Motley Fool", "title": "Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today", "image": "https://images.financialmodelingprep.com/news/why-beam-and-verve-therapeutics-shares-soared-while-eli-20231031.jpg", "site": "fool.com", "text": "The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.", "url": "https://www.fool.com/investing/2023/10/31/why-beam-and-verve-therapeutics-stock-soared-while/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-10-31T19:09:02-04:00", "date_et": "2023-10-31"}
{"symbol": "LLY", "publishedDate": "2023-11-01 06:07:07", "publisher": "MarketBeat", "title": "Investor patience tested as pharmaceutical stocks take a tumble", "image": "https://images.financialmodelingprep.com/news/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble-20231101.jpg", "site": "marketbeat.com", "text": "The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.", "url": "https://www.marketbeat.com/originals/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble/?utm_source=snapi", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-01T06:07:07-04:00", "date_et": "2023-11-01"}
{"symbol": "LLY", "publishedDate": "2023-11-01 06:55:00", "publisher": "PRNewsWire", "title": "Lilly Declares Fourth-Quarter 2023 Dividend", "image": "https://images.financialmodelingprep.com/news/lilly-declares-fourthquarter-2023-dividend-20231101.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Dec. 8, 2023 to shareholders of record at the close of business on Nov. 15, 2023.", "url": "https://www.prnewswire.com/news-releases/lilly-declares-fourth-quarter-2023-dividend-301973013.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-01T06:55:00-04:00", "date_et": "2023-11-01"}
{"symbol": "LLY", "publishedDate": "2023-11-01 08:00:00", "publisher": "PRNewsWire", "title": "Hip-Hop Classic \"It Takes Two\" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease", "image": "https://images.financialmodelingprep.com/news/hiphop-classic-it-takes-two-takes-on-new-meaning-20231101.jpg", "site": "prnewswire.com", "text": "Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative  to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature  and the benefits of complete testing Clinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) tests RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- More than 35 million adults in the U.S. have chronic kidney disease (CKD).", "url": "https://www.prnewswire.com/news-releases/hip-hop-classic-it-takes-two-takes-on-new-meaning-in-remix-to-elevate-importance-of-testing-for-kidney-disease-301973489.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-01T08:00:00-04:00", "date_et": "2023-11-01"}
{"symbol": "LLY", "publishedDate": "2023-11-01 10:34:21", "publisher": "Zacks Investment Research", "title": "Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics", "image": "https://images.financialmodelingprep.com/news/curious-about-lilly-lly-q3-performance-explore-wall-street-20231101.jpg", "site": "zacks.com", "text": "Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.", "url": "https://www.zacks.com/stock/news/2176355/curious-about-lilly-lly-q3-performance-explore-wall-street-estimates-for-key-metrics", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-01T10:34:21-04:00", "date_et": "2023-11-01"}
{"symbol": "LLY", "publishedDate": "2023-11-02 04:34:00", "publisher": "Market Watch", "title": "Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies", "image": "https://images.financialmodelingprep.com/news/weightloss-drug-maker-reports-56-profit-surge-as-it-continues-20231102.jpg", "site": "marketwatch.com", "text": "Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.", "url": "https://www.marketwatch.com/story/weight-loss-drug-maker-reports-56-profit-surge-as-it-continues-to-limit-supplies-183b19b8", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T04:34:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:30:00", "publisher": "PRNewsWire", "title": "Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity", "image": "https://images.financialmodelingprep.com/news/lilly-reports-thirdquarter-2023-financial-results-highlights-strong-sales-growth-20231102.jpg", "site": "prnewswire.com", "text": "Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.", "url": "https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2023-financial-results-highlights-strong-sales-growth-and-business-development-activity-301975008.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:30:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:36:35", "publisher": "Reuters", "title": "Eli Lilly beats quarterly revenue estimates on Mounjaro strength", "image": "https://images.financialmodelingprep.com/news/eli-lilly-beats-quarterly-revenue-estimates-on-mounjaro-strength-20231102.jpg", "site": "reuters.com", "text": "Eli Lilly beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-beats-quarterly-revenue-estimates-mounjaro-strength-2023-11-02/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:36:35-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:40:00", "publisher": "InvestorPlace", "title": "7 A-Rated Tech Stocks to Buy for November", "image": "https://images.financialmodelingprep.com/news/7-arated-tech-stocks-to-buy-for-november-20231102.jpg", "site": "investorplace.com", "text": "Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.", "url": "https://investorplace.com/2023/11/7-a-rated-tech-stocks-to-buy-for-november/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:40:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:51:00", "publisher": "Market Watch", "title": "Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed", "image": "https://images.financialmodelingprep.com/news/eli-lillys-stock-drops-after-surprise-profit-is-reported-but-20231102.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but slashed its full-year outlook, due primarily to acquired in-process research and development charges. The company swung to a net loss of $57.4 million, or 6 cents a share, from net income of $1.45 billion, or $1.61 a share, in the year-ago period.", "url": "https://www.marketwatch.com/story/eli-lillys-stock-drops-after-surprise-profit-is-reported-but-full-year-outlook-was-slashed-a2a42621", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:51:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:54:00", "publisher": "Barrons", "title": "Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically", "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-falls-as-earnings-guidance-slashed-dramatically-20231102.jpg", "site": "barrons.com", "text": "Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.", "url": "https://www.barrons.com/articles/eli-lilly-stock-earnings-4d10019a", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:54:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 06:56:18", "publisher": "CNBC", "title": "Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook", "image": "https://images.financialmodelingprep.com/news/eli-lilly-results-top-estimates-on-mounjaro-strength-but-20231102.jpeg", "site": "cnbc.com", "text": "Eli Lilly reported revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro.", "url": "https://www.cnbc.com/2023/11/02/eli-lilly-lly-q3-earnings-report-2023.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T06:56:18-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 09:00:00", "publisher": "PRNewsWire", "title": "Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting", "image": "https://images.financialmodelingprep.com/news/lilly-announces-details-of-pirtobrutinib-presentations-in-bcell-malignancies-20231102.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego. The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.", "url": "https://www.prnewswire.com/news-releases/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash-annual-meeting-301974498.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T09:00:00-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 10:56:14", "publisher": "Proactive Investors", "title": "Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook", "image": "https://images.financialmodelingprep.com/news/eli-lilly-sees-strong-3q-sales-fueled-by-mounjaro-20231102.jpg", "site": "proactiveinvestors.com", "text": "Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, marking a 44% increase from the previous quarter and surpassing analysts' estimates of $1.26 billion.", "url": "https://www.proactiveinvestors.com/companies/news/1031876?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T10:56:14-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 10:59:32", "publisher": "The Motley Fool", "title": "Why Eli Lilly Stock Is Jumping Today", "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-jumping-today-20231102.jpg", "site": "fool.com", "text": "Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates.", "url": "https://www.fool.com/investing/2023/11/02/why-eli-lilly-stock-is-jumping-today/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T10:59:32-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 12:00:56", "publisher": "CNBC", "title": "Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.", "image": "https://images.financialmodelingprep.com/news/eli-lilly-says-supply-of-blockbuster-diabetes-drug-mounjaro-20231102.jpeg", "site": "cnbc.com", "text": "The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.", "url": "https://www.cnbc.com/2023/11/02/eli-lilly-diabetes-drug-mounjaro-supply-improves-in-us.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T12:00:56-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 12:02:25", "publisher": "Zacks Investment Research", "title": "Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up", "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-q3-earnings-sales-top-eps-view-20231102.jpg", "site": "zacks.com", "text": "Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.", "url": "https://www.zacks.com/stock/news/2177427/eli-lilly-lly-q3-earnings-sales-top-eps-view-cut-stock-up", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T12:02:25-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 12:02:47", "publisher": "Zacks Investment Research", "title": "Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics", "image": "https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q3-earnings-a-look-20231102.jpg", "site": "zacks.com", "text": "While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.", "url": "https://www.zacks.com/stock/news/2177394/compared-to-estimates-lilly-lly-q3-earnings-a-look-at-key-metrics", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T12:02:47-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 13:16:08", "publisher": "Reuters", "title": "Novo Nordisk, Lilly see insatiable demand for weight-loss drugs", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-lilly-see-insatiable-demand-for-weightloss-drugs-20231102.jpg", "site": "reuters.com", "text": "Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-lilly-see-insatiable-demand-weight-loss-drugs-2023-11-02/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T13:16:08-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-02 14:07:09", "publisher": "Seeking Alpha", "title": "Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-co-lly-q3-2023-earnings-conference-20231102.jpg", "site": "seekingalpha.com", "text": "Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript", "url": "https://seekingalpha.com/article/4646632-eli-lilly-and-co-lly-q3-2023-earnings-conference-call-transcript", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-02T14:07:09-04:00", "date_et": "2023-11-02"}
{"symbol": "LLY", "publishedDate": "2023-11-03 09:45:00", "publisher": "The Motley Fool", "title": "Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?", "image": "https://images.financialmodelingprep.com/news/eli-lilly-just-added-another-potential-billiondollar-product-is-20231103.jpg", "site": "fool.com", "text": "Eli Lilly just earned FDA approval of a treatment for ulcerative colitis. There is already plenty of competition on the market for this condition.", "url": "https://www.fool.com/investing/2023/11/03/eli-lilly-just-added-another-potential-billion/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-03T09:45:00-04:00", "date_et": "2023-11-03"}
{"symbol": "LLY", "publishedDate": "2023-11-03 12:47:47", "publisher": "Zacks Investment Research", "title": "Eli Lilly Beats on Q3 Earnings: ETFs to Buy", "image": "https://images.financialmodelingprep.com/news/eli-lilly-beats-on-q3-earnings-etfs-to-buy-20231103.jpg", "site": "zacks.com", "text": "Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.", "url": "https://www.zacks.com/stock/news/2178224/eli-lilly-beats-on-q3-earnings-etfs-to-buy", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-03T12:47:47-04:00", "date_et": "2023-11-03"}
{"symbol": "LLY", "publishedDate": "2023-11-03 12:56:15", "publisher": "InvestorPlace", "title": "The Importance of Brand Power: 3 Stocks to Consider", "image": "https://images.financialmodelingprep.com/news/the-importance-of-brand-power-3-stocks-to-consider-20231103.jpg", "site": "investorplace.com", "text": "Brand power is real. The brand that consumers associate with a company is quantifiable and something valued.", "url": "https://investorplace.com/2023/11/the-importance-of-brand-power-3-stocks-to-consider/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-03T12:56:15-04:00", "date_et": "2023-11-03"}
{"symbol": "LLY", "publishedDate": "2023-11-06 15:32:00", "publisher": "Market Watch", "title": "The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli", "image": "https://images.financialmodelingprep.com/news/the-doctor-lowering-drug-prices-for-1-million-patients-20231106.jpg", "site": "marketwatch.com", "text": "Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.", "url": "https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-06T15:32:00-05:00", "date_et": "2023-11-06"}
{"symbol": "LLY", "publishedDate": "2023-11-06 15:44:53", "publisher": "Seeking Alpha", "title": "IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This", "image": "https://images.financialmodelingprep.com/news/ihe-you-better-like-eli-lilly-and-johnson-johnson-20231106.jpg", "site": "seekingalpha.com", "text": "The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Johnson & Johnson, account for over 63% of the fund's total assets, posing a concentration risk. Compared to its peers, IHE has a lower expense ratio but higher concentration of holdings, which may increase risk for investors.", "url": "https://seekingalpha.com/article/4648112-ihe-you-better-like-eli-lilly-and-johnson-and-johnson-to-buy-this", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-06T15:44:53-05:00", "date_et": "2023-11-06"}
{"symbol": "LLY", "publishedDate": "2023-11-06 16:21:13", "publisher": "Investors Business Daily", "title": "Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday", "image": "https://images.financialmodelingprep.com/news/eli-lilly-power-generators-lead-top-sp-500-performers-20231106.jpg", "site": "investors.com", "text": "Eli Lilly was an S&P 500 top performer Monday, while energy plays were among the day's biggest winners and losers.", "url": "https://www.investors.com/news/sp-500-eli-lilly-among-top-performers-monday/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-06T16:21:13-05:00", "date_et": "2023-11-06"}
{"symbol": "LLY", "publishedDate": "2023-11-07 10:32:11", "publisher": "Zacks Investment Research", "title": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-attracting-investor-attention-20231107.jpg", "site": "zacks.com", "text": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "url": "https://www.zacks.com/stock/news/2179968/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-07T10:32:11-05:00", "date_et": "2023-11-07"}
{"symbol": "LLY", "publishedDate": "2023-11-08 07:18:00", "publisher": "Market Watch", "title": "Grab these 2 funds with rich 11%-12% yields while you can", "image": "https://images.financialmodelingprep.com/news/grab-these-2-funds-with-rich-1112-yields-while-20231108.jpg", "site": "marketwatch.com", "text": "With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.", "url": "https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T07:18:00-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 08:20:00", "publisher": "The Motley Fool", "title": "Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?", "image": "https://images.financialmodelingprep.com/news/eli-lilly-slashed-its-earnings-guidance-and-its-stock-20231108.jpg", "site": "fool.com", "text": "Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.", "url": "https://www.fool.com/investing/2023/11/08/eli-lilly-slashed-its-earnings-guidance-and-its-st/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T08:20:00-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 12:20:36", "publisher": "CNBC", "title": "FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug", "image": "https://images.financialmodelingprep.com/news/fda-approves-eli-lillys-tirzepatide-for-obesity-paving-way-20231108.jpeg", "site": "cnbc.com", "text": "The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.", "url": "https://www.cnbc.com/2023/11/08/fda-approves-eli-lilly-drug-tirzepatide-for-obesity.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T12:20:36-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 12:35:59", "publisher": "Reuters", "title": "U.S. FDA approves Lilly's weight-loss drug", "image": "https://images.financialmodelingprep.com/news/us-fda-approves-lillys-weightloss-drug-20231108.jpg", "site": "reuters.com", "text": "The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, according to data on the agency's website, giving the drugmaker entry into a lucrative market that has captured Wall Street's enthusiasm this year.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lillys-weight-loss-drug-2023-11-08/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T12:35:59-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 12:45:00", "publisher": "Barrons", "title": "Eli Lilly's Obesity Drug Gets FDA Approval", "image": "https://images.financialmodelingprep.com/news/eli-lillys-obesity-drug-gets-fda-approval-20231108.jpg", "site": "barrons.com", "text": "The drug will be marketed as an obesity treatment under the name Zepbound.", "url": "https://www.barrons.com/articles/eli-lilly-obesity-drug-1aded298", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T12:45:00-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 13:22:00", "publisher": "Market Watch", "title": "Eli Lilly gets FDA approval for new obesity drug", "image": "https://images.financialmodelingprep.com/news/eli-lilly-gets-fda-approval-for-new-obesity-drug-20231108.jpg", "site": "marketwatch.com", "text": "The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co.'s LLY, +1.74% obesity drug Zepbound, which in clinical trials helped patients lose up to 48 pounds on average.", "url": "https://www.marketwatch.com/story/eli-lilly-gets-fda-approval-for-new-obesity-drug-ef514794", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T13:22:00-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 13:34:49", "publisher": "Investors Business Daily", "title": "Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug", "image": "https://images.financialmodelingprep.com/news/eli-lilly-wins-fda-approval-for-highly-anticipated-weightloss-20231108.jpg", "site": "investors.com", "text": "The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock rose less than 2% after the release.", "url": "https://www.investors.com/news/technology/eli-lilly-stock-lilly-wins-fda-approval-for-highly-anticipated-weight-loss-drug/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T13:34:49-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 14:14:42", "publisher": "Invezz", "title": "LLY stock jumps after FDA approves Eli Lilly's tirzepatide drug for weight loss", "image": "https://images.financialmodelingprep.com/news/lly-stock-jumps-after-fda-approves-eli-lillys-tirzepatide-20231108.jpg", "site": "invezz.com", "text": "Eli Lilly And Co's (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration's (FDA) approval of their blockbuster drug tirzepatide for weight loss.", "url": "https://invezz.com/news/2023/11/08/lly-stock-jumps-after-fda-approves-eli-lillys-tirzepatide-drug-for-weight-loss/?utm_source=snapi", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T14:14:42-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 15:04:18", "publisher": "Reuters", "title": "What to know about Eli Lilly's new obesity drug", "image": "https://images.financialmodelingprep.com/news/what-to-know-about-eli-lillys-new-obesity-drug-20231108.jpg", "site": "reuters.com", "text": "The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/what-know-about-eli-lillys-new-obesity-drug-2023-11-08/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T15:04:18-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 15:22:57", "publisher": "Reuters", "title": "UK's MHRA authorises Eli Lilly's Mounjaro", "image": "https://images.financialmodelingprep.com/news/uks-mhra-authorises-eli-lillys-mounjaro-20231108.jpg", "site": "reuters.com", "text": "Britain's health regulator on Wednesday authorised Eli Lilly's diabetes drug Mounjaro for weight management and weight loss in the UK.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/uks-mhra-authorises-eli-lillys-mounjaro-2023-11-08/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T15:22:57-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 15:38:33", "publisher": "Forbes", "title": "FDA Approves Diabetes Drug Mounjaro For Weight Loss Under Brand Name Zepbound", "image": "https://images.financialmodelingprep.com/news/fda-approves-diabetes-drug-mounjaro-for-weight-loss-under-20231108.jpg", "site": "forbes.com", "text": "Eli Lilly's Zepbound helped users lose up to 22.5% of their weight in clinical trials.", "url": "https://www.forbes.com/sites/britneynguyen/2023/11/08/fda-approves-diabetes-drug-mounjaro-for-weight-loss-under-brand-name-zepbound/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T15:38:33-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 16:56:00", "publisher": "PRNewsWire", "title": "Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma", "image": "https://images.financialmodelingprep.com/news/lilly-announces-extension-of-tender-offer-to-acquire-point-20231108.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (\"Shares\") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m.", "url": "https://www.prnewswire.com/news-releases/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-301982413.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T16:56:00-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 18:10:38", "publisher": "Investopedia", "title": "Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment", "image": "https://images.financialmodelingprep.com/news/eli-lilly-shares-hit-alltime-high-after-fda-approves-20231108.jpg", "site": "investopedia.com", "text": "Eli Lilly (LLY) shares hit an all-time high Wednesday after the Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and also have weight-related medical problems, such as hypertension and Type 2 diabetes.", "url": "https://www.investopedia.com/eli-lilly-shares-hit-all-time-high-after-fda-approves-drug-for-weight-loss-treatment-8399595", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T18:10:38-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 19:32:10", "publisher": "Zacks Investment Research", "title": "Earnings Estimates Come Under Pressure", "image": "https://images.financialmodelingprep.com/news/earnings-estimates-come-under-pressure-20231108.jpg", "site": "zacks.com", "text": "While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.", "url": "https://www.zacks.com/commentary/2181217/earnings-estimates-come-under-pressure", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T19:32:10-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-08 19:32:11", "publisher": "Zacks Investment Research", "title": "Earnings Estimates Come Under Pressure", "image": "https://images.financialmodelingprep.com/news/earnings-estimates-come-under-pressure-20231108.jpg", "site": "zacks.com", "text": "While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.", "url": "https://www.zacks.com/commentary/2181196/earnings-estimates-come-under-pressure", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-08T19:32:11-05:00", "date_et": "2023-11-08"}
{"symbol": "LLY", "publishedDate": "2023-11-09 07:48:59", "publisher": "Proactive Investors", "title": "'Wonder' diabetes drug Mounjaro approved in the UK", "image": "https://images.financialmodelingprep.com/news/wonder-diabetes-drug-mounjaro-approved-in-the-uk-20231109.jpg", "site": "proactiveinvestors.com", "text": "Diabetes blockbuster Mounjaro has been approved for use by the UK drugs agency MHRA after two clinical trials showed patients taking shed between 16%-22% of their weight in little more than a year. Designed to help people with diabetes, demand for US giant Eli LIlly's drug has rocketed as people have turned to it as a panacea to lose weight.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1032620?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T07:48:59-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 08:00:00", "publisher": "The Motley Fool", "title": "1 Cathie Wood Stock to Buy Hand Over Fist Right Now", "image": "https://images.financialmodelingprep.com/news/1-cathie-wood-stock-to-buy-hand-over-fist-right-20231109.jpg", "site": "fool.com", "text": "Cathie Wood's ARK Invest family of ETFs focuses on the interrelated concepts of innovation and disruption. Verve Therapeutics, a holding in two of her better-known ETFs, appears primed for a sustained move higher.", "url": "https://www.fool.com/investing/2023/11/09/1-cathie-wood-stock-to-buy-hand-over-fist-right-no/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T08:00:00-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 08:38:27", "publisher": "Reuters", "title": "Eli Lilly: still seeking UK approval on pen for weight-loss drug", "image": "https://images.financialmodelingprep.com/news/eli-lilly-still-seeking-uk-approval-on-pen-for-weightloss-20231109.jpg", "site": "reuters.com", "text": "Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-still-seeking-uk-approval-pen-weight-loss-drug-2023-11-09/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T08:38:27-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 10:23:00", "publisher": "The Motley Fool", "title": "3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates", "image": "https://images.financialmodelingprep.com/news/3-healthcare-stocks-that-have-more-than-doubled-in-20231109.jpg", "site": "fool.com", "text": "Eli Lilly's strong prospects have given investors plenty of reason to remain bullish despite rising interest rates. Axsome has gone from reporting no sales to now having a couple of strong, revenue-generating assets.", "url": "https://www.fool.com/investing/2023/11/09/3-healthcare-stocks-that-have-more-than-doubled/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T10:23:00-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 11:08:16", "publisher": "The Motley Fool", "title": "Why Eli Lilly Stock Is Slumping Today", "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-slumping-today-20231109.jpg", "site": "fool.com", "text": "The FDA approved Lilly's Zepbound (tirzepatide) for chronic weight loss management. Today's decline appears to be a case of investors \"buying the rumor and selling the news.", "url": "https://www.fool.com/investing/2023/11/09/why-eli-lilly-stock-is-slumping-today/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T11:08:16-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 13:43:19", "publisher": "Seeking Alpha", "title": "Eli Lilly's Big Win In The Obesity Space Just Got Bigger", "image": "https://images.financialmodelingprep.com/news/eli-lillys-big-win-in-the-obesity-space-just-20231109.jpg", "site": "seekingalpha.com", "text": "Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in shareholder wealth. Tirzepatide has shown promising results in clinical trials, with patients losing an average of 48 pounds over 72 weeks.", "url": "https://seekingalpha.com/article/4649863-eli-lilly-big-win-in-the-obesity-space-just-got-bigger", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T13:43:19-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-09 14:09:00", "publisher": "Barrons", "title": "Lilly Takes First Jab in Obesity Drug Showdown", "image": "https://images.financialmodelingprep.com/news/lilly-takes-first-jab-in-obesity-drug-showdown-20231109.jpg", "site": "barrons.com", "text": "Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.", "url": "https://www.barrons.com/articles/eli-lilly-novo-nordisk-stock-weight-loss-drug-d86bac08", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-09T14:09:00-05:00", "date_et": "2023-11-09"}
{"symbol": "LLY", "publishedDate": "2023-11-10 05:40:00", "publisher": "The Motley Fool", "title": "Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.", "image": "https://images.financialmodelingprep.com/news/eli-lilly-was-hoping-for-5-big-drug-launches-20231110.jpg", "site": "fool.com", "text": "Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year.", "url": "https://www.fool.com/investing/2023/11/10/eli-lilly-was-hoping-for-5-big-drug-launches-this/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T05:40:00-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 06:03:10", "publisher": "Reuters", "title": "British regulator confirms review of new pen for Lilly's Mounjaro drug", "image": "https://images.financialmodelingprep.com/news/british-regulator-confirms-review-of-new-pen-for-lillys-20231110.jpg", "site": "reuters.com", "text": "Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugmaker's Mounjaro drug against obesity and diabetes.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/british-regulator-confirms-review-new-pen-lillys-mounjaro-drug-2023-11-10/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T06:03:10-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 06:30:08", "publisher": "MarketBeat", "title": "Will Eli Lilly's Zepbound be the next big weight-loss drug?", "image": "https://images.financialmodelingprep.com/news/will-eli-lillys-zepbound-be-the-next-big-weightloss-20231110.jpg", "site": "marketbeat.com", "text": "Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.", "url": "https://www.marketbeat.com/originals/will-eli-lillys-zepbound-be-the-next-big-weight-loss-drug/?utm_source=snapi", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T06:30:08-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 06:50:00", "publisher": "The Motley Fool", "title": "The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?", "image": "https://images.financialmodelingprep.com/news/the-alzheimers-drug-market-is-heating-up-should-you-20231110.jpg", "site": "fool.com", "text": "There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.", "url": "https://www.fool.com/investing/2023/11/10/the-alzheimers-drug-market-is-heating-up-should-yo/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T06:50:00-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 07:31:27", "publisher": "Reuters", "title": "EU regulator backs Eli Lilly's Mounjaro for weight management", "image": "https://images.financialmodelingprep.com/news/eu-regulator-backs-eli-lillys-mounjaro-for-weight-management-20231110.jpg", "site": "reuters.com", "text": "Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-eli-lillys-mounjaro-weight-management-2023-11-10/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T07:31:27-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 10:23:00", "publisher": "The Motley Fool", "title": "Where Will Eli Lilly Be in 5 Years?", "image": "https://images.financialmodelingprep.com/news/where-will-eli-lilly-be-in-5-years-20231110.jpg", "site": "fool.com", "text": "Eli Lilly is pulling out all the stops to gain market share in a pair of key markets. It'll face stiff opposition from Novo Nordisk, among other contenders.", "url": "https://www.fool.com/investing/2023/11/10/where-will-eli-lilly-be-in-5-years/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T10:23:00-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 12:20:06", "publisher": "InvestorPlace", "title": "3 Stocks to Buy for Retirees Looking to Beat Inflation", "image": "https://images.financialmodelingprep.com/news/3-stocks-to-buy-for-retirees-looking-to-beat-20231110.jpg", "site": "investorplace.com", "text": "At 3.7%, inflation remains an issue. While consumer prices have come down from their peak of 9.1% in June 2022, the inflation rate in the U.S. remains well above the Federal Reserve's 2% annualized target.", "url": "https://investorplace.com/2023/11/3-stocks-to-buy-for-retirees-looking-to-beat-inflation/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T12:20:06-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 12:21:00", "publisher": "Market Watch", "title": "Here's how Eli Lilly might bring a game-changing Alzheimer's drug to market", "image": "https://images.financialmodelingprep.com/news/heres-how-eli-lilly-might-bring-a-gamechanging-alzheimers-20231110.jpg", "site": "marketwatch.com", "text": "As part of the MarketWatch 50 series, Eleanor Laise interviewed Dr. Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly & Co. LLY, +0.11%. The company's stock has soared 63% this year amid excitement for its Mounjaro treatment for Type 2 diabetes.", "url": "https://www.marketwatch.com/story/heres-how-eli-lilly-might-bring-a-game-changing-alzheimers-drug-to-market-6895dbc5", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T12:21:00-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-10 13:05:07", "publisher": "Invezz", "title": "Eli Lilly's Tirzepatide approved in the EU days after US and UK approval", "image": "https://images.financialmodelingprep.com/news/eli-lillys-tirzepatide-approved-in-the-eu-days-after-20231110.jpg", "site": "invezz.com", "text": "Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United Kingdom. The stock, took a dive on Thursday to close at $591.49 after enjoying a surge on Wednesday especially following the approval by the US FDA.", "url": "https://invezz.com/news/2023/11/10/days-after-us-and-uk-approval-eli-lillys-tirzepatide-approved-in-the-eu/?utm_source=snapi", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-10T13:05:07-05:00", "date_et": "2023-11-10"}
{"symbol": "LLY", "publishedDate": "2023-11-11 05:00:00", "publisher": "The Motley Fool", "title": "Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth", "image": "https://images.financialmodelingprep.com/news/cautious-investor-2-safe-stocks-you-also-can-count-20231111.jpg", "site": "fool.com", "text": "Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its consumer health unit.", "url": "https://www.fool.com/investing/2023/11/11/cautious-investor-2-safe-stocks-you-also-can-count/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-11T05:00:00-05:00", "date_et": "2023-11-11"}
{"symbol": "LLY", "publishedDate": "2023-11-11 13:01:04", "publisher": "Seeking Alpha", "title": "Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-presents-at-ubs-biopharma-20231111.jpg", "site": "seekingalpha.com", "text": "Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh - UBS Trung Huynh Okay. We're at the hour now.", "url": "https://seekingalpha.com/article/4650806-eli-lilly-and-company-lly-presents-ubs-biopharma-2023-conference-transcript", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-11T13:01:04-05:00", "date_et": "2023-11-11"}
{"symbol": "LLY", "publishedDate": "2023-11-13 03:22:32", "publisher": "Seeking Alpha", "title": "Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise", "image": "https://images.financialmodelingprep.com/news/eli-lilly-favorable-developments-continue-regarding-antiobesity-drug-franchise-20231113.jpg", "site": "seekingalpha.com", "text": "Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardiovascular events and has additional benefits such as weight loss. The anti-obesity drug class is projected to generate $150 billion in US revenues by 2030, with injectables being the primary choice for the next 18 months. Oral medications are expected to be approved in 2025-2026.", "url": "https://seekingalpha.com/article/4651116-eli-lilly-favorable-developments-continue-regarding-anti-obesity-drug-franchise", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T03:22:32-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 06:17:00", "publisher": "The Motley Fool", "title": "Better Buy Now: Novo Nordisk vs. Eli Lilly", "image": "https://images.financialmodelingprep.com/news/better-buy-now-novo-nordisk-vs-eli-lilly-20231113.jpg", "site": "fool.com", "text": "Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli Lilly's weight management drug Zepbound.", "url": "https://www.fool.com/investing/2023/11/13/better-buy-now-novo-nordisk-vs-eli-lilly/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T06:17:00-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 08:56:07", "publisher": "InvestorPlace", "title": "The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight'", "image": "https://images.financialmodelingprep.com/news/the-magnificent-seven-7-stocks-that-could-make-it-20231113.jpg", "site": "investorplace.com", "text": "The magnificent seven stocks have captured a lot of investor attention and investment in 2023. Those seven tech firms have been responsible for a great portion of the overall market rebound this year.", "url": "https://investorplace.com/2023/11/the-magnificent-seven-7-stocks-that-could-make-it-the-elite-eight/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T08:56:07-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 11:17:10", "publisher": "Zacks Investment Research", "title": "4 Large Drug Stocks Likely to Sail Through Industry Woes", "image": "https://images.financialmodelingprep.com/news/4-large-drug-stocks-likely-to-sail-through-industry-20231113.jpg", "site": "zacks.com", "text": "Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.", "url": "https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T11:17:10-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 11:42:55", "publisher": "Proactive Investors", "title": "Eli Lilly's experimental heart drug cuts genetic risk factor by 94% for a year", "image": "https://images.financialmodelingprep.com/news/eli-lillys-experimental-heart-drug-cuts-genetic-risk-factor-20231113.jpg", "site": "proactiveinvestors.com", "text": "Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human trial has shown. Lipoprotein (a) is a form of cholesterol that is a genetic risk factor for a range of conditions including coronary artery disease, stroke, and thrombosis.", "url": "https://www.proactiveinvestors.com/companies/news/1032929?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T11:42:55-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 13:42:01", "publisher": "New York Post", "title": "Eli Lilly's experimental drug lowers risk of heart disease by 94%: study", "image": "https://images.financialmodelingprep.com/news/eli-lillys-experimental-drug-lowers-risk-of-heart-disease-20231113.jpg", "site": "nypost.com", "text": "Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.", "url": "https://nypost.com/2023/11/13/business/eli-lillys-experimental-drug-lowers-risk-of-heart-disease-by-94-study/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T13:42:01-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-13 13:42:54", "publisher": "Proactive Investors", "title": "Eli Lilly rides on Novo's coattails as BofA analysts maintain ‘Buy' rating following SELECT trial data", "image": "https://images.financialmodelingprep.com/news/eli-lilly-rides-on-novos-coattails-as-bofa-analysts-20231113.jpg", "site": "proactiveinvestors.com", "text": "Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities said they were more favorable than expected. In a note to clients, the analysts said Nova's cardiovascular (CV) trial provides another “feather in weight-loss drugs cap,” creating a favorable set-up for Eli Lilly and Co (NYSE:LLY) and its CV outcomes trial, SURMOUNT-MMO.", "url": "https://www.proactiveinvestors.com/companies/news/1032940?SNAPI", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-13T13:42:54-05:00", "date_et": "2023-11-13"}
{"symbol": "LLY", "publishedDate": "2023-11-14 07:45:00", "publisher": "The Motley Fool", "title": "Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning", "image": "https://images.financialmodelingprep.com/news/eli-lilly-is-planning-to-dominate-the-weight-loss-20231114.jpg", "site": "fool.com", "text": "Eli Lilly's weight-loss medicine Zepbound was just approved for sale by regulators. It's buying businesses and making investments to drive further growth.", "url": "https://www.fool.com/investing/2023/11/14/eli-lilly-is-planning-to-dominate-the-weight-loss/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-14T07:45:00-05:00", "date_et": "2023-11-14"}
{"symbol": "LLY", "publishedDate": "2023-11-14 10:00:00", "publisher": "PRNewsWire", "title": "Lilly to Participate in Evercore ISI HealthCONx Conference", "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-evercore-isi-healthconx-conference-20231114.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D.", "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-evercore-isi-healthconx-conference-301986604.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-14T10:00:00-05:00", "date_et": "2023-11-14"}
{"symbol": "LLY", "publishedDate": "2023-11-14 16:06:08", "publisher": "InvestorPlace", "title": "Why It's Time to Sell These 3 Hot Stocks", "image": "https://images.financialmodelingprep.com/news/why-its-time-to-sell-these-3-hot-stocks-20231114.jpg", "site": "investorplace.com", "text": "Stock gains are great, but they don't necessarily continue forever. Today's fast rising investment can be tomorrow's disappointment.", "url": "https://investorplace.com/2023/11/why-its-time-to-sell-these-3-hot-stocks/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-14T16:06:08-05:00", "date_et": "2023-11-14"}
{"symbol": "LLY", "publishedDate": "2023-11-14 16:33:00", "publisher": "PRNewsWire", "title": "Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma", "image": "https://images.financialmodelingprep.com/news/lilly-announces-the-receipt-of-nrc-consent-in-connection-20231114.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission (\"NRC\") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the \"NRC Consent\"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares (\"Shares\") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.", "url": "https://www.prnewswire.com/news-releases/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma-301988209.html", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-14T16:33:00-05:00", "date_et": "2023-11-14"}
{"symbol": "LLY", "publishedDate": "2023-11-14 18:46:01", "publisher": "Reuters", "title": "Investors increase holdings of weight-loss drug makers' shares in Q3 -filings", "image": "https://images.financialmodelingprep.com/news/investors-increase-holdings-of-weightloss-drug-makers-shares-in-20231114.jpg", "site": "reuters.com", "text": "Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/investors-increase-holdings-weight-loss-drug-makers-shares-q3-filings-2023-11-14/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-14T18:46:01-05:00", "date_et": "2023-11-14"}
{"symbol": "LLY", "publishedDate": "2023-11-15 14:04:47", "publisher": "Reuters", "title": "Lilly plans single-digit billion dollar new German plant - sources", "image": "https://images.financialmodelingprep.com/news/lilly-plans-singledigit-billion-dollar-new-german-plant-sources-20231115.jpg", "site": "reuters.com", "text": "U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a press conference for Friday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-plans-single-digit-billion-dollar-new-german-plant-sources-2023-11-15/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-15T14:04:47-05:00", "date_et": "2023-11-15"}
{"symbol": "LLY", "publishedDate": "2023-11-15 18:00:00", "publisher": "The Motley Fool", "title": "Why Eli Lilly Stock Flopped While the Market Popped Today", "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-flopped-while-the-market-popped-20231115.jpg", "site": "fool.com", "text": "A media report stated that the pharmaceutical giant intends to build a new factory in Germany. It will apparently fund the project entirely on its own.", "url": "https://www.fool.com/investing/2023/11/15/why-eli-lilly-stock-flopped-while-the-market-poppe/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-15T18:00:00-05:00", "date_et": "2023-11-15"}
{"symbol": "LLY", "publishedDate": "2023-11-16 05:17:37", "publisher": "Reuters", "title": "Eli Lilly plans to invest 2 bln euros in new German plant -source", "image": "https://images.financialmodelingprep.com/news/eli-lilly-plans-to-invest-2-bln-euros-in-20231116.jpg", "site": "reuters.com", "text": "U.S. pharma company Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-invest-2-bln-euros-new-german-plant-source-2023-11-16/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-16T05:17:37-05:00", "date_et": "2023-11-16"}
{"symbol": "LLY", "publishedDate": "2023-11-16 06:19:09", "publisher": "Seeking Alpha", "title": "Eli Lilly: Perfectly Priced Healthcare Giant", "image": "https://images.financialmodelingprep.com/news/eli-lilly-perfectly-priced-healthcare-giant-20231116.jpg", "site": "seekingalpha.com", "text": "Eli Lily has the highest market capitalization of any Healthcare company, but its low revenue does not justify its lofty valuation at first glance. However, the company's average 5-year forward growth of 16.8% explains the market's pricing of its stock. With a steady pipeline of products with a high focus on Diabetes/Obesity drugs, the company's outlook certainly justifies its position as the highest-valued healthcare stock.", "url": "https://seekingalpha.com/article/4652291-eli-lilly-perfectly-priced-healthcare-giant", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-16T06:19:09-05:00", "date_et": "2023-11-16"}
{"symbol": "LLY", "publishedDate": "2023-11-16 06:26:17", "publisher": "Reuters", "title": "Eli Lilly plans new 2 billion euro German plant -source", "image": "https://images.financialmodelingprep.com/news/eli-lilly-plans-new-2-billion-euro-german-plant-20231116.jpg", "site": "reuters.com", "text": "U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-new-2-bln-euro-german-plant-source-2023-11-16/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-16T06:26:17-05:00", "date_et": "2023-11-16"}
{"symbol": "LLY", "publishedDate": "2023-11-16 08:30:08", "publisher": "Investors Business Daily", "title": "This Option Trade On Eli Lilly Stock Could Return 27% By Mid-January", "image": "https://images.financialmodelingprep.com/news/this-option-trade-on-eli-lilly-stock-could-return-20231116.jpg", "site": "investors.com", "text": "This iron condor trade on Lilly stock has the potential to return 27% if the stock price stays between about 510 and 680.", "url": "https://www.investors.com/research/options/eli-lilly-stock-option-trade-benefits-from-decay/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-16T08:30:08-05:00", "date_et": "2023-11-16"}
{"symbol": "LLY", "publishedDate": "2023-11-16 09:00:00", "publisher": "The Motley Fool", "title": "Better Growth Stock: Novo Nordisk vs. Eli Lilly", "image": "https://images.financialmodelingprep.com/news/better-growth-stock-novo-nordisk-vs-eli-lilly-20231116.jpg", "site": "fool.com", "text": "Novo Nordisk and Eli Lilly are both leaders in the diabetes care market. Both have been recording excellent financial results for most of the year.", "url": "https://www.fool.com/investing/2023/11/16/better-growth-stock-novo-nordisk-vs-eli-lilly/", "ticker": "LLY", "event_date": "2023-11-02", "window_start": "2023-10-26", "window_end": "2023-11-16", "publishedDateET": "2023-11-16T09:00:00-05:00", "date_et": "2023-11-16"}
